espite the transformative potential of cell and gene therapies, widespread adoption remains limited due to systemic gaps in infrastructure, reimbursement models, and coordination of care.

In this report, you’ll learn from experts commenting on key challenges and emerging solutions within this space, including how cell gene therapies are revolutionizing patient care while creating new challenges for us as an industry.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.

A surge of generics, biosimilars, and innovative therapies are expected in 2025, addressing conditions from cancer to chronic diseases.

Journavx is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are...

IPD Analytics joins as Networking partner for the 14th Annual Pharma IPR India Conference

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

Trump has reversed some of President Biden’s initiatives, but so far the healthcare elements of the Inflation Reduction Act remain unchanged

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting.

Gene therapies for rare blood disorders show promise with reduced crises and improved life quality, despite high costs and slow adoption.

CAR T-cell therapy offers hope for multiple myeloma, showing efficacy in trials but challenges in antigen targeting and tumor infiltration.

CRISPR Therapeutics faces challenges despite FDA approval for a breakthrough therapy, with slow progress impacting stock performance.

Gene therapies are very labor intensive, so despite their life-saving potential, access to and utilization of these therapies is a challenge

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars...

Uncover the reasons behind the limited adoption of gene therapies for sickle cell disease at the AMCP Nexus 2024.

Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something...

Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and...

issues affecting payer uptake and provider adoption of biosimilars in the US, such as economic considerations, clinical evidence, and market

Jeffrey Casberg, MS, RPh, senior vice president of pharmacy at IPD Analytics, discussed the FDA approvals of new drugs and pricing.